Christian Baumeier, Ganna Aleshcheva, Dominik Harms, Ulrich Gross, Christian Hamm, Birgit Assmus, Ralf Westenfeld, Malte Kelm, Spyros Rammos, Philip Wenzel, Thomas Münzel, Albrecht Elsässer, Mudather Gailani, Christian Perings, Alae Bourakkadi, Markus Flesch, Tibor Kempf, Johann Bauersachs, Felicitas Escher, Heinz-Peter Schultheiss
Myocarditis in response to COVID-19 vaccination has been reported since early 2021. In particular, young male individuals have been identified to exhibit an increased risk of myocardial inflammation following the administration of mRNA-based vaccines. Even though the first epidemiological analyses and numerous case reports investigated potential relationships, endomyocardial biopsy (EMB)-proven cases are limited. Here, we present a comprehensive histopathological analysis of EMBs from 15 patients with reduced ejection fraction (LVEF = 30 (14-39)%) and the clinical suspicion of myocarditis following vaccination with Comirnaty® (Pfizer-BioNTech) ( n = 11), Vaxzevria® (AstraZenica) ( n = 2) and Janssen® (Johnson & Johnson) ( n = 2)...
June 22, 2022: International Journal of Molecular Sciences